---
title: "Alivus Life Sciences Ltd (ALIVUS) — Share Price, Financials & Analysis"
symbol: "ALIVUS"
company: "Alivus Life Sciences Ltd"
canonical: "https://tapetide.com/stocks/ALIVUS"
isin: "INE03Q201024"
nse_symbol: "ALIVUS"
bse_code: "543322"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 17015.37
generated_at: "2026-09-13T18:56:42.233Z"
---

# Alivus Life Sciences Ltd (ALIVUS)

Canonical page: https://tapetide.com/stocks/ALIVUS

## Company

- **NSE Symbol:** ALIVUS
- **BSE Code:** 543322
- **ISIN:** INE03Q201024
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2021-08-06
- **CEO:** Dr. Yasir Yusufali Rawjee Ph.D.
- **Employees:** 2203
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** glenmarklifesciences.com

## About

Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.

## Latest Price

- **Price:** ₹1386.8
- **Change:** -3.4 (-0.24%)
- **Open:** ₹1385
- **Day High:** ₹1398.1
- **Day Low:** ₹1376.1
- **Previous Close:** ₹1390.2
- **Volume:** 74367
- **As Of:** 2026-09-11T10:21:11+00:00

## Key Fundamentals

Observed at 2026-09-11T04:36:09.547147Z.

- **Market Cap:** ₹17015.37 Cr
- **Classification:** Smallcap
- **P/E (reported):** 28.3
- **P/E (TTM):** 28.22
- **EPS (TTM):** ₹49.14
- **EPS (reported):** ₹36.48
- **Book Value:** ₹271.41
- **Price to Book:** 5.13
- **Dividend Yield:** 0.36%
- **ROE:** 16.94%
- **ROCE:** 21.78%
- **Debt to Equity:** 0.02
- **Revenue (yearly):** ₹2612.2 Cr
- **Net Income:** ₹564.5 Cr
- **EBITDA:** ₹857.7 Cr
- **52-Week High:** ₹1493.8
- **52-Week Low:** ₹819
- **RSI (14):** 57.04

## Tapetide Score

- **Score:** 64 / 100
- **Score date:** 2026-09-04
- **Archetype:** Quality at a Reasonable Price
- **What it means:** Financial strength is not being paid for with a demanding multiple. The question worth asking is whether the quality is durable or reflects a good patch — check the consistency of returns over several years rather than the latest quarter.
- **Pillar profile:** Quality: Good · Valuation: Cheap · Momentum: Rising
- **Percentile:** 95.6 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 82.64 | 9% |
| growth | 29.73 | 9% |
| momentum | 77.64 | 12% |
| ownership | 53.43 | 24% |
| quality | 70.35 | 22% |
| valuation | 64.72 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 27.4%

### Weaknesses

- The company has delivered a poor sales growth of 6.24% over past five years.
- Company has high debtors of 153 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 44.41% | 36.73% | -5.38% |
| ebitda margin growth | -1.35% | 10.84% | 9.8% | 11.29% |
| net income growth | -1.6% | 16.25% | 6% | 9% |
| revenue growth | -6.9% | 7.88% | 6% | 6% |
| roce | — | -2.42% | -17% | 25.46% |
| roe | — | -1.74% | 18.12% | -16.88% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| Expenses | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 |
| Operating Profit | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 |
| OPM % | 28 | 30 | 26 | 27 | 27 | 30 | 31 | 29 | 30 | 34 | 31 | 33 |
| Other Income | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 |
| Profit before tax | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 |
| Tax % | 25 | 26 | 24 | 26 | 25 | 26 | 26 | 25 | 25 | 24 | 25 | 25 |
| Net Profit | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| EPS in Rs | 9.69 | 9.69 | 7.99 | 9.1 | 7.78 | 11.18 | 11.58 | 9.91 | 10.6 | 12.25 | 13.25 | 13.04 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 886 | 1537 | 1885 | 2123 | 2161 | 2283 | 2387 | 2552 | 2590 |
| Expenses | 0 | 638 | 1064 | 1294 | 1506 | 1518 | 1608 | 1702 | 1754 | 1754 |
| Operating Profit | 0 | 248 | 473 | 592 | 617 | 643 | 675 | 684 | 798 | 837 |
| OPM % | -4 | 28 | 31 | 31 | 29 | 30 | 30 | 29 | 31 | 32 |
| Other Income | 0 | 0 | 11 | 0 | 14 | 28 | 11 | 33 | 34 | 48 |
| Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 | 5 | 5 |
| Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 53 | 61 | 75 | 79 |
| Profit before tax | 0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 | 751 | 801 |
| Tax % | 4200 | 14 | 26 | 25 | 26 | 26 | 25 | 26 | 25 | — |
| Net Profit | 0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 564 | 603 |
| EPS in Rs | -430 | 997.86 | 1597.37 | 358.74 | 34.17 | 38.11 | 38.43 | 39.63 | 45.99 | 49.14 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 61 | 110 | 59 | 13 | 11 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.01 | 2 | 2 | 2 | 25 | 25 | 25 | 25 | 25 |
| Reserves | -1 | 86 | 400 | 751 | 2030 | 2114 | 2308 | 2793 | 3308 |
| Borrowings | 0 | 0 | 0 | 0 | 3 | 19 | 17 | 57 | 57 |
| Other Liabilities | 1 | 1387 | 1324 | 1244 | 414 | 545 | 501 | 537 | 594 |
| Total Liabilities | 0 | 1475 | 1726 | 1997 | 2471 | 2702 | 2850 | 3411 | 3983 |
| Fixed Assets | 0 | 456 | 546 | 573 | 595 | 781 | 805 | 955 | 1038 |
| CWIP | 0 | 80 | 11 | 14 | 92 | 62 | 106 | 102 | 284 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 478 | 780 |
| Other Assets | 0 | 939 | 1169 | 1410 | 1784 | 1860 | 1939 | 1877 | 1881 |
| Total Assets | 0 | 1475 | 1726 | 1997 | 2471 | 2702 | 2850 | 3411 | 3983 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 10 | 195 | 388 | 598 | 306 | 414 | 392 | 565 |
| Cash from Investing Activity | 0 | -9 | -51 | -69 | -122 | -147 | -116 | -616 | -570 |
| Cash from Financing Activity | 0 | 1 | -137 | -214 | -79 | -388 | -279 | -6 | -64 |
| Net Cash Flow | 0 | 2 | 8 | 106 | 397 | -228 | 18 | -230 | -69 |
| Free Cash Flow | 0 | 1 | 144 | 322 | 466 | 143 | 285 | 226 | 259 |
| CFO/OP | 4800 | 14 | 61 | 84 | 119 | 71 | 85 | 81 | 93 |

### Ratios

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 44 | 185 | 152 | 120 | 116 | 136 | 122 | 148 | 153 |
| Inventory Days | 162 | 441 | 227 | 214 | 185 | 224 | 251 | 237 | 246 |
| Days Payable | 41 | 201 | 111 | 92 | 110 | 158 | 139 | 137 | 132 |
| Cash Conversion Cycle | 165 | 424 | 268 | 241 | 190 | 202 | 235 | 248 | 267 |
| Working Capital Days | -2059 | -186 | -37 | 12 | 149 | 176 | 188 | 201 | 194 |
| ROCE % | — | 529 | 186 | 97 | 42 | 30 | 28 | 25 | 24 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 82.85% | 82.85% | 82.85% | 82.85% | 75% | 75% | 74.99% | 74.94% | 74.91% | 74.91% | 74.87% | 74.87% |
| FIIs | 4.38% | 4.57% | 5.01% | 4.82% | 7.85% | 6.74% | 6.57% | 6.42% | 6.84% | 5.09% | 5.29% | 5.54% |
| DIIs | 0.64% | 0.59% | 1.4% | 1.57% | 4.16% | 4.86% | 5.19% | 5.61% | 5.47% | 7.12% | 7.28% | 7.18% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 9.2% | 9.2% | 9.09% | 9.13% | 10.63% | 10.99% | 10.5% | 10.34% | 10.14% | 10.21% | 9.87% | 10.05% |
| Others | 2.92% | 2.79% | 1.64% | 1.64% | 2.36% | 2.41% | 2.74% | 2.69% | 2.64% | 2.67% | 2.69% | 2.36% |
| No. of Shareholders | 198764 | 185531 | 156183 | 149396 | 143960 | 146840 | 141977 | 138500 | 135643 | 132748 | 127969 | 125559 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 11 / 5 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1399.04 | Sell |
| EMA (10) | 1387.91 | Sell |
| SMA (20) | 1382.86 | Buy |
| EMA (20) | 1371.02 | Buy |
| SMA (50) | 1276.63 | Buy |
| EMA (50) | 1294.46 | Buy |
| SMA (100) | 1173.27 | Buy |
| EMA (100) | 1204 | Buy |
| SMA (200) | 1050.58 | Buy |
| EMA (200) | 1118.91 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 56.36 | Neutral |
| MACD (12,26,9) | 30.05 | Sell |
| Stochastic (14,3,3) | 36.87 | Neutral |
| ADX (14) | 40.49 | Buy |
| Williams %R (14) | -66.96 | Neutral |
| ATR (14) | 51.03 | High Volatility |
| ROC (12) | 1.91 | Buy |
| Stoch RSI (14) | 8.65 | Buy |
| UO (7,14,28) | 34.44 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 4 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 4 analyst ratings, observed at 2026-09-11T04:36:06.839373+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8 May - Alivus Life Sciences schedules Q4 FY26 and FY26 earnings call on May 15, 2026, 8:30–9:30 a.m. IST. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8 May - Alivus Life Sciences schedules Q4 FY26 and FY26 earnings call on May 15, 2026, 8:30–9:30 a.m. IST.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/461cee59-f236-4e40-8d52-1b1e507fdee6.pdf) |
| 7 May - Submitted Annual Secretarial Compliance Report for FY2025-26 under SEBI Regulation 24A. | [Compliances-Reg.24(A)-Annual Secretarial Compliance 7 May - Submitted Annual Secretarial Compliance Report for FY2025-26 under SEBI Regulation 24A.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a51011b4-45c6-4796-89b1-9c1cd7261d2e.pdf) |
| 7 May - Board meets May 14, 2026 to approve FY26 audited results and consider dividend; trading window closes Apr 1-May 16. | [Board Meeting Intimation for Considering And Approving Audited Financial Results Of The Company For The Quarter And Year Ended 31St March, 2026 And To Consider And Recommend Dividend, If Any, On Equity Shares For The Year Ended March 31, 2026. 7 May - Board meets May 14, 2026 to approve FY26 audited results and consider dividend; trading window closes Apr 1-May 16.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/3d9cd737-b1b6-4216-bd75-126cc2257ae4.pdf) |
| 6 Mar - Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 6 Mar - Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4e0ceda0-4b7c-4ab0-bf3e-a729ec7c3b9c.pdf) |
| 30 Jan - Q3 FY26: Revenue Rs.673cr, EBITDA Rs.245cr, PAT Rs.150cr; guide high-single-digit growth, 30–32% margins, Rs.450cr CAPEX. | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 30 Jan - Q3 FY26: Revenue Rs.673cr, EBITDA Rs.245cr, PAT Rs.150cr; guide high-single-digit growth, 30–32% margins, Rs.450cr CAPEX.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/81b8547b-3699-4956-b982-474f88ea4a53.pdf) |
| 29 Apr - Alivus Life Sciences confirms it is not a Large Corporate under SEBI circular, April 29, 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 29 Apr - Alivus Life Sciences confirms it is not a Large Corporate under SEBI circular, April 29, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/be46304d-87f1-4dd5-95ac-e62c445629d9.pdf) |
| 29 Apr - Alivus Life Sciences confirms it is not a Large Corporate under SEBI circular, April 29, 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 29 Apr - Alivus Life Sciences confirms it is not a Large Corporate under SEBI circular, April 29, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/be46304d-87f1-4dd5-95ac-e62c445629d9.pdf) |
| 25 Feb - Fire on Feb 14 at Dahej block; API unaffected; API restart Mar 1; intermediates mid-March; some shipments delayed. | [Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015, As Amended ('SEBI Listing Regulations') 25 Feb - Fire on Feb 14 at Dahej block; API unaffected; API restart Mar 1; intermediates mid-March; some shipments delayed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9b7b6797-f650-472b-a2ce-d3a053f68e2e.pdf) |
| 21 Mar - Income Tax Dept assessment order dated 20 Mar 2026 demands Rs 2,60,67,810 for AY 2023-24; company to appeal. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 21 Mar - Income Tax Dept assessment order dated 20 Mar 2026 demands Rs 2,60,67,810 for AY 2023-24; company to appeal.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1d654d05-be90-4c27-802e-b1c0cb7750ac.pdf) |
| 2 Feb - Alivus to attend three in-person investor conferences in Mumbai on Feb 10, 11 and 26, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Feb - Alivus to attend three in-person investor conferences in Mumbai on Feb 10, 11 and 26, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9b1fb71a-3c0c-494a-9efd-d86796a0cd8e.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-08 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99ff4934-04fc-455f-a518-147402b44f70.pdf) |
| 2026-09-08 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f4cf33a5-4e36-427e-a2fd-0a66d031319b.pdf) |
| 2026-09-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a664c197-2400-4078-9cc7-b02bbaeb2410.pdf) |
| 2026-09-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fafd2613-d35a-4e9c-99f4-afbbc705ec9f.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ff9f658-79f5-47b7-8f77-31db370947ec.pdf) |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Acquisition](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2c21fc62-af99-4bf9-9210-d4cb0f5197aa.pdf) |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=73b6250a-2146-474a-91f4-8ecf0a7597c8.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=043aa6ce-9544-4cdd-8a76-fb70c21b5fc3.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8e7d953-9d5f-4441-be71-fe854ba66b15.pdf) |
| 2026-08-11 | [Notice Of 15Th Annual General Meeting Of The Company For FY 2025-26 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d659f29-07af-464e-9219-ef060fa19667.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-07 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7c3ddc5a-ccf9-4418-9dfb-73aac001c622.pdf) |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0ba0e04-82cd-4b3e-b8a9-ad4deec0d0e5.pdf) |
| 2026-01-30 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=81b8547b-3699-4956-b982-474f88ea4a53.pdf) |
| 2025-11-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3f8e4217-f830-4a36-8fc3-7582ac309ce9.pdf) |
| 2025-08-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=af2b02e0-9dd7-45cf-9b7e-36dd0e85829a.pdf) |
| 2025-05-23 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79318563-47a8-499a-990a-1e34b991aea7.pdf) |
| 2024-08-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33d99fa1-82a2-4424-b066-36565368ce9b.pdf) |
| 2024-05-03 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86dbe2fa-8e54-4b3b-bbfa-80979a129a5c.pdf) |
| 2024-01-31 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6fbc8804-cd7f-430a-83c6-4ed9abb7b8a3.pdf) |
| 2023-10-25 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5eefc359-c628-4518-8e3b-054326c34319.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5875b6fb-ebd0-4529-99c7-9d8b8eac887c.pdf) |
| 2026-05-15 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b98130e-c389-472b-822a-b6cdb9879296.pdf) |
| 2026-01-22 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=da60cf05-a6ac-4426-8c8b-c833afce6850.pdf) |
| 2025-11-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7ee542a3-6cf5-4d38-ac35-528c1fe26150.pdf) |
| 2025-08-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6caea94-c20b-45cd-b0c4-d48165f6619a.pdf) |
| 2025-05-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7ad8557d-8703-4fd4-a37c-e358335e5d40.pdf) |
| 2024-10-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d780dc9a-b5be-4597-953d-9748e5681e09.pdf) |
| 2024-07-26 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be0d5d30-d90e-4438-b422-14e049b187ac.pdf) |
| 2024-04-26 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=788eded2-2410-4ba1-8159-b9f5fe42ab44.pdf) |
| 2024-01-24 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbd5862d-9595-4774-ad9e-89b1845962d1.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-30 | [Unaudited Financial Results For The First Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8135ef08-7fef-4ce9-a625-b74ee0405541.pdf) |
| 2026-05-14 | [Audited Financial Results For The Quarter And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=531b2b26-212b-4bc0-bbb8-81427ff0a3cc.pdf) |
| 2026-01-22 | [Unaudited Financial Results For The Third Quarter And Nine Months Ended 31 December 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=257004bd-fe6e-47bb-99d3-c5b6b7e201a4.pdf) |
| 2025-11-06 | [Unaudited Financial Results For The Second Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=03c976ff-796d-4b11-8cdc-6c05276745bc.pdf) |
| 2025-08-01 | [Unaudited Financial Results For The First Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=698425f2-b287-4aa8-9ee0-db5d3dc8b678.pdf) |
| 2025-05-15 | [Audited Financial Results For The Fourth Quarter And Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b3c3165f-d4bd-4e4b-bd89-cb71e7f1cdd2.pdf) |
| 2025-01-23 | [Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e21e6b69-26e5-492f-b7f0-c857d3254ec8.pdf) |
| 2024-10-24 | [Unaudited Finanacial Results For The Second Quarter And Half Year Ended 30Th September 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1ce153b4-0caf-4e40-9583-fd95c6b51220.pdf) |
| 2024-07-25 | [Unaudited Financial Results For The First Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f8645a78-cbce-474a-9f94-74cb940c372e.pdf) |
| 2024-04-25 | [Audited Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4425b5d-9f06-471f-882b-e95c00b92ac0.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa5554f6-8d4a-4388-8a92-f791022934b1.pdf) |
| 2026-05-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=828a9dab-be3c-414f-a329-9ff0bf198f52.pdf) |
| 2026-01-22 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=512b006a-0a27-4139-9724-eba7013ba461.pdf) |
| 2025-11-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=456b8f18-4155-43de-b301-ca96c323a1de.pdf) |
| 2025-08-01 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c28a52f-fa3c-4117-9f2f-6a4cb2351915.pdf) |
| 2025-05-15 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad68d0b2-95b0-496b-af6d-7f7b2325e3a8.pdf) |
| 2025-01-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d4a2401-f8d5-40d1-bc29-a9d6a7537501.pdf) |
| 2024-10-24 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e76d4a86-7399-4723-be60-a7e79244454a.pdf) |
| 2024-07-25 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=90ee7efe-a0f6-4393-9ac0-6923563905d6.pdf) |
| 2024-04-25 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f5da7756-cb58-4feb-b494-526ce47cc641.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8df8a6d9-81cb-435e-8052-6b92c8a5ad9e.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8df8a6d9-81cb-435e-8052-6b92c8a5ad9e.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5eefc359-c628-4518-8e3b-054326c34319.pdf) |
| Oct 2022 | [Concall - Oct 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/528a8126-0e2f-4d0c-8473-8c0e7ae51f0e.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3f8e4217-f830-4a36-8fc3-7582ac309ce9.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4479f3b7-f07d-40e3-a42e-c65938e2f552.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fca0df87-b624-46b2-ae30-2337ca312407.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7fc23f73-8248-4c98-8586-ed763b498515.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a0ba0e04-82cd-4b3e-b8a9-ad4deec0d0e5.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a0ba0e04-82cd-4b3e-b8a9-ad4deec0d0e5.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2022 from nse](https://archives.nseindia.com/annual_reports/AR_20957_GLS_2021_2022_30082022130205_08302022140001.zip) |
| from nse | [Financial Year 2010 from nse](https://archives.nseindia.com/annual_reports/AR_STERLINBIO_2010_2010_15062012101925.zip) |
| from nse | [Financial Year 2009 from nse](https://archives.nseindia.com/annual_reports/AR_STERLINBIO_2009_2009_18082010121500.zip) |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/39af4dd1-5f5b-49cb-ad67-1a41eefe35c2.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/daaf54ff-eb86-4644-8715-0b30eac8e16e.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4c85c84e-713e-443d-a19c-f0f38cf16b4f.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ba6c5c9b-aadd-434b-b826-773aa2434f28.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/543322/74964543322.pdf) |
| from bse | [Financial Year 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport//5122990317.pdf) |
| from bse | [Financial Year 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport//5122990316.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:56:42.233Z.